+44 (0) 1223 755950
+1 832 327 7413
Patritumab
REQUEST MORE INFO
Catalogue No: abx831241
Price:
US$464.00
(Size: 100 µg)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Patritumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ERBB3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
Research Articles on ERBB3
| Target | ERBB3 |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA, WB |
| Host | Human |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Isotype | IgG1 Kappa |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Buffer | 0.01 M PBS. pH 7.4. |
| CAS Number | 1262787-83-6 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 7-12 working days. |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |